pd 98059 has been researched along with Cancer of Endometrium in 12 studies
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source
2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These observations were reinforced in endometrial cancer cells by PD98059 treatment." | 1.46 | IGFBP-rP1 acts as a potential tumor suppressor via the suppression of ERK signaling pathway in endometrial cancer cells. ( Ding, Y; Jiang, J; Lu, B; Ma, Y; Xu, T; Zhang, Y, 2017) |
| "However, a direct role for leptin in endometrial cancer has not been demonstrated." | 1.37 | Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation. ( Gong, C; Liu, Y; Lv, L; Sheng, H; Wang, D; Xiao, W; Yin, J, 2011) |
| "Human endometrial carcinoma Ishikawa cells were cultured in vitro." | 1.37 | [Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice]. ( Guo, RX; Qiao, YH; Shi, HR; Wang, XY; Zhang, RF, 2011) |
| "Leptin may promote the proliferation of endometrial cancer Ishikawa cells by activating ERK1/2 signaling pathway." | 1.34 | [The role of ERK1/2 in leptin promoting the proliferation of human endometrial cancer cell line Ishikawa]. ( Gong, C; Liu, Y; Sheng, H; Wang, DH; Xiao, W; Yin, J, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Lu, Y | 1 |
| Lu, H | 1 |
| Yang, X | 1 |
| Song, W | 1 |
| Ma, Y | 1 |
| Jiang, J | 1 |
| Zhang, Y | 1 |
| Ding, Y | 1 |
| Xu, T | 1 |
| Lu, B | 1 |
| Zhang, G | 1 |
| Cheng, Y | 1 |
| Zhang, Q | 1 |
| Li, X | 1 |
| Zhou, J | 1 |
| Wang, J | 1 |
| Wei, L | 1 |
| Chen, HX | 1 |
| Xu, XX | 1 |
| Tan, BZ | 1 |
| Zhang, Z | 1 |
| Zhou, XD | 1 |
| Liu, Y | 2 |
| Lv, L | 1 |
| Xiao, W | 2 |
| Gong, C | 2 |
| Yin, J | 2 |
| Wang, D | 1 |
| Sheng, H | 2 |
| Guo, RX | 1 |
| Zhang, RF | 1 |
| Wang, XY | 1 |
| Shi, HR | 1 |
| Qiao, YH | 1 |
| Leong, H | 1 |
| Riby, JE | 1 |
| Firestone, GL | 1 |
| Bjeldanes, LF | 1 |
| Vivacqua, A | 1 |
| Bonofiglio, D | 1 |
| Recchia, AG | 1 |
| Musti, AM | 1 |
| Picard, D | 1 |
| Andò, S | 1 |
| Maggiolini, M | 1 |
| Wang, DH | 1 |
| Munir, I | 2 |
| Fukunaga, K | 2 |
| Miyazaki, K | 2 |
| Okamura, H | 2 |
| Miyamoto, E | 2 |
| Kanasaki, H | 1 |
| Ohba, T | 1 |
| Lee, H | 1 |
| Jiang, F | 1 |
| Wang, Q | 1 |
| Nicosia, SV | 1 |
| Yang, J | 1 |
| Su, B | 1 |
| Bai, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Serum Autotaxin as a Potential Biomarker in Systemic Lupus Erythematosus Patients and Its Relation to Disease Activity.[NCT06063668] | 94 participants (Anticipated) | Observational | 2023-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
12 other studies available for pd 98059 and Cancer of Endometrium
| Article | Year |
|---|---|
BarH-like homeobox 1 induces the progression of cell malignant phenotype in endometrial carcinoma through the regulation of ERK/MEK signaling pathway.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Survival; Endometrial Neoplasms; Extracellular Sign | 2021 |
IGFBP-rP1 acts as a potential tumor suppressor via the suppression of ERK signaling pathway in endometrial cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cy | 2017 |
ATX‑LPA axis facilitates estrogen‑induced endometrial cancer cell proliferation via MAPK/ERK signaling pathway.
Topics: Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease Progression; Endometrial Neo | 2018 |
MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
Topics: Androstadienes; Animals; Cell Line, Tumor; Endometrial Neoplasms; Female; Flavonoids; Gene Expressio | 2017 |
Leptin activates STAT3 and ERK1/2 pathways and induces endometrial cancer cell proliferation.
Topics: Adenocarcinoma; Cell Line, Tumor; Cell Proliferation; Endometrial Neoplasms; Enzyme Inhibitors; Fema | 2011 |
[Effects of PD98059 and LY294002 on subcutaneous xenograft of human endometrial carcinoma in nude mice].
Topics: Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relat | 2011 |
Potent ligand-independent estrogen receptor activation by 3,3'-diindolylmethane is mediated by cross talk between the protein kinase A and mitogen-activated protein kinase signaling pathways.
Topics: Adenocarcinoma; Anticarcinogenic Agents; Cyclic AMP Response Element-Binding Protein; Cyclic AMP-Dep | 2004 |
The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Topics: Androstadienes; Cell Proliferation; Endometrial Neoplasms; Enzyme Activation; Enzyme Inhibitors; Est | 2006 |
[The role of ERK1/2 in leptin promoting the proliferation of human endometrial cancer cell line Ishikawa].
Topics: Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Endometrial Neoplasms; Femal | 2007 |
Mitogen-activated protein kinase activation and regulation of cyclooxygenase 2 expression by platelet-activating factor and hCG in human endometrial adenocarcinoma cell line HEC-1B.
Topics: Adenocarcinoma; Androstadienes; Antineoplastic Agents, Hormonal; Chorionic Gonadotropin; Cyclic AMP; | 1999 |
Expression of cyclooxygenase 2 by prostaglandin E(2) in human endometrial adenocarcinoma cell line HEC-1B.
Topics: Adenocarcinoma; Cyclooxygenase 2; Dinoprostone; Endometrial Neoplasms; Enzyme Activation; Enzyme Inh | 2000 |
MEKK1 activation of human estrogen receptor alpha and stimulation of the agonistic activity of 4-hydroxytamoxifen in endometrial and ovarian cancer cells.
Topics: Endometrial Neoplasms; Enzyme Activation; Enzyme Inhibitors; Estrogen Antagonists; Estrogen Receptor | 2000 |